Add It Up: 3 Things to Consider for Capacity Expansion
Technology, Disruptive Innovation and Partnerships that are Revolutionizing How Medicines Are Made
Overcoming Scale Up Process Development Challenges for Pluripotent Stem Cell Derived Therapies
Future-Proofing Cell Therapy Production
Unlocking the Potential of Advanced Therapies Through Collaborations
Why So Shy? Implementing Disruptive Technologies with Confidence in Cell Therapy

Add It Up: 3 Things to Consider for Capacity Expansion

26 Jan 2022
Briefing Room

Scalable. Flexible. Established. These are three things to look for when adding manufacturing capacity for cell therapies, plasmids, viral vectors, mAbs, and more. Cytiva’s FlexFactory™ manufacturing platforms deliver all three – to 100 organizations on 6 continents. Hear from others who’ve added capacity before you choose a solution to help turn your innovative idea into a clinical and commercial reality. Because patients are waiting for life-changing therapies, and yours could be one of them.

Shannon Eaker, Cell and Gene Therapy Enterprise Technical Leader, Cytiva


Carol Houts, Vice President, Quality and Business Strategy, Germfree

Matthew M. Hewitt, Executive Director, Scientific Services Cell and Gene Therapy, Charles River

Michael Paglia, Chief Operating Officer, Elevate Bio

Raymond D. Stapleton, Ph.D., Executive Vice President, Pharmaceutical Sciences and Manufacturing, Genocea

Erwin Cammaart, Executive Director, Process Development, Iovance Biotherapeutics, Inc.



Shannon Eaker
Cell and Gene Therapy Enterprise Technical Leader
Michael Paglia
Chief Operating Officer
Elevate Bio
Carol Houts
Vice President, Quality and Business Strategy
Matthew Hewitt
Senior Director, Scientific Services, Cell and Gene Therapy
Charles River
Dr Raymond Stapleton
Executive Vice President, Pharmaceutical Services and Manufacturing
Erwin Cammaart
Executive Director, Process Development
Iovance Biotherapeutics Inc